Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Enobia Pharma brings in $15mm of potential $47mm via Series D; round reaches $40mm

Executive Summary

In what appears to be its fourth financing round, Enobia Pharma Inc. (developing drugs for genetic bone disorders for which there are no available treatments) raised $15mm from seven undisclosed investors. According to the Form D filing, the company could raise up to $47mm in three tranches. Enobia’s last fund-raise was an August 2009 Series C that generated $50mm; that money was expected to last through mid-2011.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies